Sign in
Taking people in United StatesPhase 3

Tests brenetafusp with nivolumab against standard nivolumab treatments in advanced melanoma

Tests brenetafusp plus nivolumab in adults with untreated advanced melanoma.

Key facts

Who runs it
Immunocore Ltd
Where
Aurora, Boston, Charlottesville, Chicago, Columbus, Dallas, Denver, Detroit, Edgewood, Farmington, Greenville, Hackensack, Jacksonville, Knoxville, La Jolla, Lake Success, Los Angeles, Miami, Minneapolis, Nashville, New York, Palo Alto, Philadelphia, Pittsburgh, Richmond, Salt Lake City, Santa Monica, Seattle, Spartanburg, St Louis, Tucson, Washington D.C., and Westwood, United StatesSee the 37 sitesAlso in 25 other countries, 173 sites
Registry title
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Status
Recruiting
Phase
Phase 3
People taking part
680 people, planned
Started
5 Jun 2024
Expected to end
16 Oct 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Brenetafusp
  • Nivolumab
  • Nivolumab + Relatlimab
Record updated
25 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced melanoma that has not been treated before and who are HLA-A*02:01-positive.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Melanoma confirmed under the microscope as Stage IV, or Stage III that cannot be removed by surgery. The disease must be measurable (RECIST 1.1). ECOG performance status must be 0 or 1.
Earlier treatment
No earlier systemic anticancer treatment for melanoma that cannot be removed by surgery or has spread.
Biomarker or test result
HLA-A*02:01-positive. BRAF V600 mutation status must be known. A tumor tissue sample (archived or fresh) must be confirmed as adequate.

Main reasons for not taking part

  • Another cancer in the past, other than the one treated in this trial
  • Untreated, active or symptomatic cancer spread to the brain or spinal cord area (CNS metastases or carcinomatous meningitis)
  • Active autoimmune disease that needs treatment lowering the immune system
  • Significant lung or heart disease or poor lung or heart function
  • Past life-threatening side effect from earlier anti-PD-(L)1 or anti-LAG-3 treatment

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Participants must be HLA-A*02:01-positive
  • Participants must have histologically confirmed Stage IV or unresectable Stage III melanoma
  • Archived or fresh tumor tissue sample that must be confirmed as adequate
  • Participants must have measurable disease per RECIST 1.1
  • Participant must have BRAF V600 mutation status determined
  • Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control from the study screening date until 5 months after the final dose of study intervention

Who cannot take part

  • Participants who received prior systemic anticancer therapy for unresectable or metastatic melanoma
  • Participants with a history of a life-threatening AE related to prior anti-PD-(L)1 or anti-LAG-3
  • Participants with a history of a malignant disease other than those being treated in this study
  • Hypersensitivity to IMC-F106C, nivolumab, relatlimab, or any associated excipients
  • Participants with clinically significant pulmonary disease or impaired lung function
  • Participants with clinically significant cardiac disease or impaired cardiac function
  • Participants with active autoimmune disease requiring immunosuppressive treatment
  • Participants with any medical condition that is poorly controlled or that would, in the Investigator's or Sponsor's judgment, adversely impact the participant's participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results
  • Participants with untreated, active, or symptomatic central nervous system (CNS) metastases or carcinomatous meningitis

Where in United States

Also in 25 other countries, 173 sites

  • University of Colorado Anschutz Medical CampusAurora, United StatesContact: Kayla VondranTaking people
  • Dana-Farber Cancer InstituteBoston, United StatesContact: Linnea DrewTaking people
  • Massachusetts General HospitalBoston, United StatesContact: Kamaneh Montazeri, MDTaking people
  • UVA Health-UVA Emily Couric Clinical Cancer CenterCharlottesville, United StatesTaking people
  • Northwestern University - Robert H. Lurie Comprehensive Cancer Center - NMDTIChicago, United StatesTaking people
  • The Ohio State UniversityColumbus, United StatesContact: Sierra CimafrancaTaking people
  • University of Texas, SouthwesternDallas, United StatesContact: Desiree PierreTaking people
  • The Melanoma & Skin Cancer InstituteDenver, United StatesContact: Brandon KeithTaking people
  • Henry Ford Cancer Center - MichiganDetroit, United StatesContact: Bethany AdamsTaking people
  • St. Elizabeth Healthcare - EdgewoodEdgewood, United StatesContact: Elizabeth Beatty, CRCTaking people
  • UConn Health-Farmington (University of Connecticut Health Center (UCHC))Farmington, United StatesNo longer taking part
  • Prisma Health Cancer InstituteGreenville, United StatesContact: Lisa JohnsonTaking people
  • John Theurer Cancer Center at Hackensack University Medical CenterHackensack, United StatesContact: Oncology Clinical Research Referral OfficeTaking people
  • Mayo Clinic FloridaJacksonville, United StatesContact: Heidi TurnerTaking people
  • The University of Tennessee - Knoxville (UTK)Knoxville, United StatesContact: Megan McKenzie, RNTaking people
  • University of California San DiegoLa Jolla, United StatesContact: Katie O'NeilTaking people
  • Northwell Health Cancer InstituteLake Success, United StatesContact: Sarilee LizTaking people
  • ESC Norris Comprehensive Cancer CenterLos Angeles, United StatesContact: Sandy TranTaking people
  • The Angeles Clinic and Research Institute- West Los AngelesLos Angeles, United StatesContact: Saba MukarramTaking people
  • UCLA Hematology-OncologyLos Angeles, United StatesContact: Jessica CrockerTaking people
  • University of Miami Health System-Sylvester Comprehensive Cancer Center-MiamiMiami, United StatesTaking people
  • Allina Health Cancer Institute - MinneapolisMinneapolis, United StatesContact: Jonathan AlexanderTaking people
  • Sarah Cannon Research Institute: USA/TNNashville, United StatesTaking people
  • Tennessee Oncology, PLLCNashville, United StatesContact: Mindy JordanTaking people
  • Columbia University Medical CenterNew York, United StatesNo longer taking part
  • Stanford Cancer Institute - Stanford Cancer Center Palo AltoPalo Alto, United StatesNo longer taking part
  • Thomas Jefferson UniversityPhiladelphia, United StatesContact: Madeleine MartinelliTaking people
  • UPMC Hillman Cancer CenterPittsburgh, United StatesContact: Kelly SchroderTaking people
  • Virginia Commonwealth University (Vcu) Massey Cancer CenterRichmond, United StatesContact: Faith McFaddenTaking people
  • University of Utah - Huntsman Cancer InstituteSalt Lake City, United StatesContact: Shantae GeorgeTaking people
  • Saint John's Health Center - John Wayne Cancer Institute (JWCI)Santa Monica, United StatesContact: Maribel RamirezTaking people
  • Swedish Medical Center - Swedish Cancer Institute (SCI) - First Hill CampusSeattle, United StatesContact: CancerResearchTaking people
  • Spartanburg Regional Healthcare System - Spartanburg Medical Center (SMC)Spartanburg, United StatesContact: Kristen Ford, RN MSNTaking people
  • Washington University School of MedicineSt Louis, United StatesNo longer taking part
  • University of ArizonaTucson, United StatesContact: Terri KatzTaking people
  • Georgetown UniversityWashington D.C., United StatesTaking people
  • The University of Kansas Cancer Center (KUCC) - WestwoodWestwood, United StatesContact: CT Nurse NavigatorTaking people

About the trial

What the trial wants to find out

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma.

The 3 groups in the trial

  • Arm A: Brenetafusp Low Dose + NivolumabTreatment being tested

    Participants receive brenetafusp Low Dose once weekly (QW) for the first 13 weeks, then every 2 weeks (Q2W) through Week 51, and then every 4 weeks (Q4W). Nivolumab is given Q4W. Closed to randomization after dose recommendation by the IDMC in November 2025.

    Treatment: Brenetafusp and Nivolumab

  • Arm B: Brenetafusp High Dose + NivolumabTreatment being tested

    Participants receive brenetafusp High Dose once weekly (QW) for the first 13 weeks, then every 2 weeks (Q2W) through Week 51, and then every 4 weeks (Q4W). Nivolumab is given Q4W. Selected as go-forward experimental arm after dose recommendation by the IDMC in November 2025

    Treatment: Brenetafusp and Nivolumab

  • Arm C: Nivolumab OR Nivolumab + RelatlimabExisting treatment, for comparison

    Participants receive nivolumab 480 mg monotherapy, or nivolumab 480 mg + relatlimab 160 mg, Q4W.

    Treatment: Nivolumab and Nivolumab + Relatlimab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301
Plain-language title
Tests brenetafusp with nivolumab against standard nivolumab treatments in advanced melanomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
25 February 2026